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Novel targeted siRNA-loaded hybrid 
nanoparticles: preparation, characterization 
and in vitro evaluation
Nneka Dim1, Maryna Perepelyuk1, Olukayode Gomes1, Chellappagounder Thangavel2, Yi Liu2, Robert Den2, 
Ashakumary Lakshmikuttyamma1 and Sunday A. Shoyele1*
Abstract 
Background: siRNAs have a high potential for silencing critical molecular pathways that are pathogenic. Neverthe-
less, their clinical application has been limited by a lack of effective and safe nanotechnology-based delivery system 
that allows a controlled and safe transfection to cytosol of targeted cells without the associated adverse effects. Our 
group recently reported a very effective and safe hybrid nanoparticle delivery system composing human IgG and 
poloxamer-188 for siRNA delivery to cancer cells. However, these nanoparticles need to be optimized in terms of 
particle size, loading capacity and encapsulation efficiency. In the present study, we explored the effects of certain 
production parameters on particle size, loading capacity and encapsulation efficiency. Further, to make these nano-
particles more specific in their delivery of siRNA, we conjugated anti-NTSR1-mAb to the surface of these nanoparticles 
to target NTSR1-overexpressing cancer cells. The mechanism of siRNA release from these antiNTSR1-mAb functional-
ized nanoparticles was also elucidated.
Results: It was demonstrated that the concentration of human IgG in the starting nanoprecipitation medium and 
the rotation speed of the magnetic stirrer influenced the encapsulation efficiency, loading capacity and the size of the 
nanoparticles produced. We also successfully transformed these nanoparticles into actively targeted nanoparticles 
by functionalizing with anti-NTSR1-mAb to specifically target NTSR1-overexpressing cancer cells, hence able to avoid 
undesired accumulation in normal cells. The mechanism of siRNA release from these nanoparticles was elucidated 
to be by Fickian diffusion. Using flow cytometry and fluorescence microscopy, we were able to confirm the active 
involvement of NTSR1 in the uptake of these anti-NTSR1-mAb functionalized hybrid nanoparticles by lung adenocar-
cinoma cells.
Conclusions: This hybrid nanoparticle delivery system can be used as a platform technology for intracellular delivery 
of siRNAs to NTSR1-overexpressing tumor cells.
Keywords: Nanoparticles, Targeted siRNA delivery, siRNA, Hybrid nanotechnology, Controlled release, Release 
kinetics
© 2015 Dim et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
siRNAs have a high potential to silence critical molecu-
lar pathways that are pathogenic. They can potentially 
restore sensitivity of different types of cancers to con-
ventional/targeted therapies by silencing some pathways 
responsible for reducing or eliminating the sensitivi-
ties of tumors to known therapies [1]. The emergence of 
this novel technology has consequently led to multiple 
siRNA-based agents reaching various stages of clinical 
trials. The discovery of RNAi interference has simulta-
neously encouraged the development of various delivery 
systems to help to fully harness the benefits of siRNA in 
cancer therapy. This is more so, since the use of siRNAs 
in cancer therapy has been limited by a lack of efficient 
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nanotechnology-based delivery system to ensure an effi-
cient and safe delivery of this unique technology to spe-
cific cells while avoiding healthy cells in the process [2, 
3]. Our group recently reported the use of a novel hybrid 
nanoparticle delivery system for the efficient and safe 
delivery of siRNA against mutant KRAS in A549 lung 
adenocarcinoma cells [4]. This nanoparticle technol-
ogy takes advantage of the benefits derived from human 
immunoglobulin G (human IgG) and poloxamer-188 
(polyoxyethylene-polyoxypropylene block co- polymer), 
for stable and efficient siRNA delivery [4]. Human IgG is 
the main component of these nanoparticles encapsulating 
the loaded siRNA. The inclusion of human IgG antibody 
helps to reduce/eliminate well documented immunogenic 
reaction experienced with most nanoparticle formula-
tions [4]. Poloxamer-188, a nonionic triblock copolymer, 
has been previously used as a stealth polymer to prevent 
macrophageal uptake of nanoparticles hence circumvent-
ing the reticulo-endothelial system (RES) during systemic 
circulation. It was suggested that it reduces opsonization 
by serum proteins, hence reducing macrophage uptake 
[5, 6]. The delivery of anti-mutant KRAS-siRNA using 
these unique nanoparticles led to a stable knockdown of 
the target gene. Consequently, a restoration of sensitiv-
ity of A549 cells to EGFR-tyrosine kinase inhibitors was 
demonstrated [4]. The loaded siRNA was also protected 
from serum nuclease showing these nanoparticles are 
capable of delivering stable siRNAs to the cytoplasm of 
target cells [4]. Overall, these novel hybrid nanoparticles 
showed a great potential as a platform technology for 
safe and effective delivery of siRNA for oncogene knock-
down in cancer cells. However, these nanoparticles still 
need to be optimized in terms of particle size, nanopar-
ticle yield, encapsulation efficiency, and loading capacity. 
In this study, we investigate how certain nanoprecipita-
tion parameters could be explored in order to optimize 
the size and loading efficiency of siRNA. Further, several 
reports have shown that active targeted drug delivery 
has allowed better delivery of loaded drugs (payload) to 
cancer cells [7–9]. In this present study, we explored the 
possibility of functionalizing these siRNA-loaded hybrid 
nanoparticles with anti-neurotensin receptor 1 monoclo-
nal antibody (anti-NTSR1 mAb) in order to convert these 
nanoparticles to an active targeted nanoparticle delivery 
system for delivering siRNAs to non-small lung cancer 
cells (NSCLC) using NTSR1 as a delivery target. NTSR1 
has been shown by immunohistochemistry to be overex-
pressed in approximately 60  % of lung adenocarcinoma 
[8]. In early stages of NSCLC, NTSR1 was one of the 
first 50 genes upregulated and associated with disease-
free survival [10]. We hope to take advantage of this over 
expression in NSCLC to achieve an optimized targeting 
of siRNA to NSCLC by conjugating anti-NTSR1-mAb 
to the surface of our hybrid nanoparticles. The conju-
gation of anti-NTSR1 mAb to these nanoparticles was 
confirmed using FT-IR and fluorescence spectroscopy. 
Using anti-mutant KRAS-siRNA, and siGLO-green as 
our model siRNAs, we hoped to verify the involvement 
of NTSR1 in the internalization of siRNA-loaded hybrid 
nanoparticles in A549 and H23 lung adenocarcinoma 
cell lines. Further, we aimed to elucidate the mechanisms 
and kinetics of siRNA release from these nanoparticles in 
different physiological conditions using various mathe-
matical models including zero-order, first order, Higushi, 
Hixson-Croswell and Korsmeyer-Peppas models [11, 12].
Results
Nanoparticle Preparation and characterization
siRNA-loaded hybrid nanoparticles composing of human 
IgG in the inner layer and poloxamer-188 in the outer 
layer were prepared using our previously reported nano-
precipitation process [4]. The nanoparticles formed were 
mostly spherical in shape, as seen in Fig. 1a, irrespective 
of the conditions used. The multilayered structure of the 
nanoparticles was confirmed using transmission electron 
microscope as seen in Fig. 1b. The effects of human IgG 
concentration and magnetic stirring rate on particle size, 
PDI, zeta potential, encapsulation efficiency and loading 
capacity of hybrid nanoparticles are presented in Table 1. 
Table 1 shows that the concentration of human IgG and 
the magnetic stirring rate influenced the particle size, 
encapsulation efficiency (EE) and loading capacity (LC) 
of corresponding nanoparticle formulations. However, 
no such influence was observed for the PDI and zeta 
potential. EE and LC were calculated from the following 
equations:
where A is the total amount of siRNA, B is the free 
siRNA, and C is the weight of nanoparticles in grams.
The conjugation of anti-NTSR1-mAb to the surface 
of IP-3 nanoparticle formulation led to an increase in 
the particle size of these functionalized nanoparticles as 
compared to the corresponding non-functionalized nan-
oparticles. A change in zeta potential was also observed 
with the functionalized nanoparticles producing a zeta 
potential of 0.0 while the corresponding non-functional-
ized nanoparticles produced a zeta potential of +16.7. All 
the batches produced nanoparticles with narrow particle 
size distribution as indicated by the PDI values.
Conjugation of anti‑NTSR1‑mAb to hybrid nanoparticles
80 % of the thiolated anti-NTSR1-mAb used in the conju-
gation reaction was found to couple to the nanoparticles 
% EE = (A− B)/A× 100
% LC = (A− B)/C × 100
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from the protein analysis performed using Total Protein 
Kit. Further, a total of 20  mg of anti-NTSR1-mAb was 
calculated to be attached to 1 g of functionalized hybrid 
nanoparticles. FT-IR was used to confirm the cova-
lent conjugation of anti-NTSR1-mAb to the nanopar-
ticles. Figure  2 demonstrates the distinctive differences 
between the spectra generated for the functionalized 
and non-functionalized hybrid nanoparticles. To verify 
the presence of anti-NTSR1-mAb on the surface of the 
nanoparticles, the fluorescent intensity obtained from 
the coupling of FITC-labelled sheep antimurine IgG to 
anti-NTSR1-mAb on the surface of the functionalized 
nanoparticles was compared to that of the non-func-
tionlized nanoparticle control. Table 2 demonstrates the 
increased fluorescent intensity of the anti-NTSR1-mAb 
nanoparticles when compared to the other samples sug-
gesting the presence of ant-NTSR1-mAb on the surface 
of the hybrid nanoparticles.
In vitro release study
The release of anti-mutant KRAS siRNA from both anti-
NTSR1-mAb functionalized hybrid nanoparticles and 
non-functionalized hybrid nanoparticles was compared 
at pH values 5 and 7.4. Figure 3 demonstrates the lack of 
Fig. 1 Diagrammatic representation and TEM micrograph of the produced nanoparticle. a Nanoparticles at lower magnification. b Nanoparticles at 
higher magnification to show the internal arrangement of the components
Table 1 The effects of  variable parametes on  particle size, PDI, zeta potential, encapsulation efficiency and  loading 
capacity of nanoparticles (Mean ± SD, n = 3)
PDI polydispersity index
Nanoparticle batch Particle size  
(NM)
PDI Zeta potential  
(mV)
Encapsulation  
efficiency (%)
Loading 
capacity (%)
IP-1 672.4 ± 17.9 0.08 ± 0.02 +17.1 ± 0.8 41.1 ± 0.2 0.71 ± 0.02
IP-2 424.6 ± 12.4 0.04 ± 0.01 +17.3 ± 0.4 50.2 ± 0.4 1.23 ± 0.03
IP-3 135.4 ± 5.4 0.07 ± 0.03 +16.7 ± 0.2 60 ± 0.4 2.04 ± 0.06
IP3-anti-NTSR1-mAb 140.2 ± 2.4 0.2 ± 0.04 0.0 ± 0.3 N/A N/A
IP-4 716.1 ± 15.2 0.1 ± 0.04 +17.4 ± 0.4 35.4 ± 0.4 0.62 ± 0.04
IP-5 545.3 ± 14.3 0.06 ± 0.03 +17.9 ± 0.3 40.3 ± 0.3 0.81 ± 0.03
IP-6 389.2 ± 11.4 0.06 ± 0.05 +17.5 ± 0.4 48.5 ± 0.5 1.21 ± 0.05
IP-7 820.5 ± 12.4 0.08 ± 0.03 +17.4 ± 0.5 30.3 ± 0.1 0.53 ± 0.02
IP-8 799.3 ± 11.4 0.1 ± 0.04 +16.9 ± 0.6 37.3 ± 0.3 0.65 ± 0.03
IP-9 589.3 ± 10.4 0.09 ± 0.05 +17.2 ± 0.3 42.6 ± 0.4 0.82 ± 0.04
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any discernable differences in the release profile of siRNA 
from both nanoparticle formulations (functionalized and 
non-functionalized) at the respective pH values. How-
ever, a limitation in the release of siRNA from both nano-
particle formulations was demonstrated at pH 7.4 when 
compared to the release profile at pH 5.
Release kinetics and mechanisms of siRNA release
Using several mathematical models including zero-order, 
first-order, Higuchi, Hixson–Crowell, and Korsmeyer–
Peppas models, the kinetics and mechanisms of siRNA 
release from both functionalized and non-functionalized 
hybrid nanoparticles were evaluated using correlation 
values (R2) and release parameters determined from the 
results of model fitting of the release profiles. The results 
presented in Tables 3 and 4 suggest that the release of the 
siRNA from both types of nanoparticles at pH 5 was by 
Fickian diffusion. A definite mechanism could not be elu-
cidated for the release at pH 7.4.
NTSR1 expression in non‑small lung cancer cells
Reverse transcriptase PCR was used to confirm the 
expression of NTSR1 in two non-small cell lung cancer 
cells: A549 and H23 to ensure that these cells actually 
express the receptor. Figure 4 demonstrates the positive 
expression of this target receptor in both cells.
Cellular uptake of anti‑NTSR1‑mAb functionalized hybrid 
nanoparticles
The involvement of neurotensin receptor 1 in the inter-
nalization of siGLO-loaded NTSR1-functionalized hybrid 
nanoparticles by A549 and H23 cells was accessed using 
both fluorescence microscopy and flow cytometry analysis. 
Figures 5 and 6 demonstrate the inhibitory effect of excess 
concentration of neurotensin on the internalization of siGLO 
as demonstrated by the absence of siGLO in the cytosol of 
the respective cell lines after 6  h. However, the absence of 
neurotensin in the cell culture enhanced the internalization 
of siGLO in the cells as demonstrated Figs. 5 and 6.
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Fig. 2 -FI-IR spectra showing the conjugation of anti-NTSR1-mAb to hybrid nanoparticles (a) incomparison to non-functionalized nanoparticles (b)
Table 2 Fluorecent intensities of  anti-NTSR1-mAb func-
tionalized hybrid nanoparticles was compared to  that 
of  the non-functionalized, PBS solution and  free sheep 
antimurine IgG labelled with FITC (Mean ± SD, n = 3)
Sample Fluorescent intensity
Anti-NTSR1-mAb functionalized nanoparticles 2435.1 ± 7.5
Non-functionalized nanoparticles 436.2 ± 3.4
PBS 314.3 ± 5.1
Sheep antimurine IgG-FITC 1134 ± 10.3
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We were able to quantify the effect of neurotensin 
receptor 1 on the internalization of siGLO using flow 
cytometry. Figure 7 demonstrates a significant inhibition 
of the internalization of siGLO since only approximately 
20 % internalization was observed in both cells following 
inhibition by neurotensin.
Discussion
The main objective of this study was to optimize critical 
parameters in our recently reported novel hybrid nano-
particles composing human IgG and poloxamer-188. 
This is to make them more efficient as a nanotechnology-
based delivery platform for siRNAs. We also aimed to 
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Fig. 3 Comparison of in vitro siRNA release profile from siRNA encapsulated anti-NTSR1-mAb functionalized and non-functionalized nanoparticles 
at pH 5 and 7. siRNA was more efficiently released at pH 5 due to the superior solubility of human IgG at that pH. Functionalization of the nanoparti-
cles did not seem to affect the release rate at each of the pH values. n = 3 for each sample point
Table 3 Mathematical models and parameters based on siRNA release data from non-functionalized nanoparticles
PH Correlation (R) n value for  
Korsmeyer–Peppas
Zero order First‑order Higuchi Hixson–Crowell Korsmeyer–Peppas
7.4 0.6578 0.3456 0.6877 0.3455 0.5456 0.35
5 0.4567 0.5673 0.9856 0.4563 0.9856 0.67
Table 4 Mathematical models and parameters based on siRNA release data from NTSR1-functionalized nanoparticles
PH Correlation (R) n value for  
Korsmeyer–Peppas
Zero order First‑order Higuchi Hixson–Crowell Korsmeyer–Peppas
7.4 0.4537 0.6784 0.4579 0.4536 0.4563 0.34
5 0.4567 0.4675 0.9754 0.5647 0.9789 0.64
Page 6 of 13Dim et al. J Nanobiotechnol  (2015) 13:61 
transform these hybrid nanoparticles into an active tar-
geted platform for delivery of siRNAs to NTSR1 express-
ing tumors by covalently attaching anti-NTSR1-mAb 
to the surface of these nanoparticles and to confirm the 
involvement of NTSR1 in the uptake of these nanoparti-
cles by cancer cells. The mechanism of release of encap-
sulated siRNA in different physiological pH conditions 
was also elucidated.
The impact of particle size on the cellular internali-
zation efficiency of nanoparticles has been variously 
reported [15–17]. It has also been previously reported 
that the size of the nanoparticles plays a key role in their 
adhesion to and interaction with biological cells [18]. In 
view of this, it is extremely important for any nanoparti-
cle technology intended for intracellular delivery of siR-
NAs to be able to produce size-tuneable nanoparticles. In 
this study, we explored the effect of certain factors such 
as the concentration of the human IgG and the magnetic 
stirring rate during the nanoprecipitation process on 
critical parameters such as particle size, siRNA encapsu-
lation efficiency (EE) and loading capacity (LC). Data in 
Table 2 demonstrates that an increase in the concentra-
tion of human IgG in the nanoprecipitation medium led 
to a decrease in the EE and LC. This result is consistent 
with previously reported chitosan nanoparticles pro-
duced by increasing the concentration of chitosan in the 
production process [11, 12]. This is probably due to the 
fact that an increase in the amount of human IgG led to 
an increase in the number of nanoparticles formed which 
subsequently led to lesser amount of siRNA available for 
encapsulation in each nanoparticle since the concentra-
tion of the siRNA was kept consistent for all the nanopar-
ticle batches produced. In case of the size of nanoparticle 
produced, an increase in the magnetic stirring rate led 
to a decrease in the size of the nanoparticles produced. 
A decrease in nanoparticle size was achieved due to an 
A549 H23
NTSR-1
β-actin
Fig. 4 Reverse transcriptase PCR showing the expression of neu-
rotensin receptor 1 (NTSR1) in A549 and H23 cell lines
Fig. 5 Fluorescence micrograph showing the delivery of siGLO into the cytosol of A549 cells using the NTSR1-mAb-functionalized hybrid nanopar-
ticles. The upper panel shows the inhibition of siGLO delivery following an initial treatment of the cells with neurotensin
Page 7 of 13Dim et al. J Nanobiotechnol  (2015) 13:61 
increase in the shear rate brought about by the increase 
in the stirring rate of the magnet during the production 
of the nanoparticles [19]. The particle size of the nano-
particles were stable following storage at ambient and 
4 °C conditions for 1 month. Following the optimization 
of the particle size, EE and LC, the nanoparticle batch 
with the optimum parameters in terms of particle size, 
EE and LC was selected as the nanoparticle formulation 
for further development. Nanoparticle formulation IP-3 
with particle size 135 nm, EE of 60 % and LC of 2.04 % 
was selected for functionalization with anti-NTSR1-mAb 
to transform it to an actively targeted hybrid nanoparticle 
system for siRNA delivery. To achieve the conjugation of 
anti-NTSR1-mAb to prepared hybrid nanoparticles, the 
primary amines of anti-NTSR1-mAb was thiolated using 
2-iminothiolane (Traut’s reagent) as previously reported 
[3, 11]. PMPI was used as a sulfhydryl and hydroxyl-
reactive linker and was conjugated to the hydroxyl groups 
present in poloxamer-188 on the surface of the hybrid 
nanoparticles [13]. The isocyanate end of PMPI reacted 
with the hydroxyl group on the nanoparticles to form 
carbamate linkage while the maleimide end reacted with 
the sulfhydryl groups in the thiolated anti-NTSR1 [13]. 
The reaction steps are shown in Fig. 8. The particle size 
of anti-NTSR1-mAb functionalized nanoparticles was 
higher than the corresponding non-functionalized nan-
oparticles. The increase in size may be attributed to the 
conjugation of the mAb to the surface of the nanoparti-
cles. Further, the fact that several centrifugation steps 
and lyophilisation were involved in the conjugation pro-
cess may also contribute to the increase in particle size 
[11, 20]
Fig. 6 Fluorescence micrograph showing the delivery of siGLO into the cytosol of H23 cells using the NTSR1-mAb-functionalized hybrid nanoparti-
cles. The upper panel shows the inhibition of siGLO delivery following an initial treatment of the cells with neurotensin
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Fig. 7 Probing the effect of inhibition of neurotensin receptor 1 
(NTSR1) with neurotensin on the internalization of siRNA-loaded 
targeted hybrid nanoparticles in A549 and H23 cells using flow 
cytometry (n = 3)
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FT-IR (Fig. 2) was used to confirm the conjugation of 
anti-NTSR1-mAb to the nanoparticles. The spectrum of 
non-functionalized hybrid nanoparticles has an absorp-
tion peak at 3276 cm−1. This peak has been attributed to 
the stretching vibration from the OH hydroxyl group in 
poloxamer-188 present on the surface of the nanopar-
ticles [21]. This peak can also be seen in the spectrum 
for anti-NTSR1-mAb functionalized nanoparticles, 
however, with lesser intensity. This decrease in inten-
sity suggests the conjugation of the hydroxyl group to 
another molecule. The linker PMPI used for the conju-
gation of anti-NTSR1-mAb to the nanoparticles reacts 
with the hydroxyl groups in poloxamer-188 as shown in 
the reaction in Fig. 8. The absorption peak at 853 cm−1 
in the anti-NTSR1-mAb functionalized nanoparticles 
has been attributed to the para-substituted aromatic 
ring in PMPI. This peak is conspicuously absent in the 
non-functionalized nanoparticles spectrum suggesting 
the presence of the linker on the surface of the function-
alized nanoparticles. The absorption peak at 1149  cm−1 
in both spectral confirms the presence of the C–O–C 
stretching vibration from the ether group in polox-
amer-188. The absorption peak at 688 cm−1 seen in the 
anti-NTSR1-mAb functionalized nanoparticles spec-
trum is due to the thioether bond (C–S–C) connect-
ing the anti-NTSR1-mAb to PMPI on the surface of the 
nanoparticles [22]. This important peak is conspicuously 
absent in the spectrum of the non-functionalized nano-
particles. The differences in the both spectra confirm the 
successful conjugation of anti-NTSR1-mAb to the hybrid 
nanoparticles.
Fluorescence spectroscopy was also used to confirm the 
presence of anti-NTSR1-mAb on the surface of the nano-
particles [9]. Nanoparticles functionalized with antibody 
Fig. 8 Reaction schemes for the attachment of anti-NTSR1-mAb to hybrid nanoparticles
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demonstrated a significantly higher fluorescent intensity 
because of the presence of anti-NTSR1-mAb on the sur-
face of the nanoparticles. This allowed the nanoparticles 
to bind significantly to sheep antimurine IgG-FITC when 
compared to the non-functionalized nanoparticles.
Recently, active targeted nanoparticles have enabled 
better and more efficient delivery of payload to cancer 
cells. These actively targeted nanoparticles are usually 
achieved via covalent conjugation of a specific mAb to 
nanoparticle surface, which recognizes and bind to a spe-
cific receptor/biomarker expressed in tumors [7, 9, 23]. 
However, it has recently been reported that the transfor-
mation of these nanoparticles to actively targeted nano-
particle by surface functionalization with mAb could 
inadvertently inhibit the release of the payload in physi-
ological fluids [11]. To ensure that the anti-NTSR1-mAb 
functionalization of these novel hybrid does not inhibit 
the release of the loaded siRNA in certain physiological 
fluids, we attempted to elucidate the mechanisms and 
release kinetics of siRNA from both functionalized and 
non-functionalized hybrid nanoparticles at pH 7 and 5. 
These pH values were chosen in order to simulate the 
pH of different body fluids including that of a cancer 
microenvironment. Figure  3 demonstrates the pH sen-
sitive nature of these nanoparticle delivery systems. At 
pH value of 7, very limited amount of the loaded anti-
mutant-KRAS siRNA (approximately 20 %) was released 
throughout the study period. The limited release of 
siRNA at pH 7 could be attributed to the reduced/limited 
solubility of IgG at the pH. Proteins are known to have 
limited solubility at pH values close to their isoelectric 
point (pI) [24, 25]. Since the pI of IgG is 7, its solubility 
at neutral pH values is quite limited. This makes it dif-
ficult for encapsulated siRNAs to be released at this pH 
value, hence possibly limiting their release extracellu-
larly. However, at slightly acidic pH value of 5, an optimal 
siRNA release of approximately 100 % was obtained due 
to the solubility of IgG at this pH. An optimal release of 
the loaded siRNA is very desirable at pH 5, as pH 5 rep-
resents the acidic condition of the endosome/lysosome 
[26, 27]. This is important since endosome is the normal 
site of intracellular siRNA release [4, 28]. Further, the 
lack of differences in the release profile of the non-func-
tionalized and anti-NTSR1-mAb-functionalized nano-
particles at the respective pH values suggests that the 
presence of the anti-NTSR1-mAb on the surface of the 
functionalized nanoparticles does not affect the release of 
the loaded siRNA. This is contrary to a previous report 
which showed that conjugated mAb on the surface of 
nanoparticles adversely affected the release of the pay-
load, erlotinib [11]. The reason for this difference could 
be attributed to the fact that antimutant-KRAS siRNA 
has a high aqueous solubility, allowing the uninhibited 
diffusion of siRNA through the hybrid nanoparticles 
despite the presence of mAb on the surface. On the con-
trary, erlotinib has a very poor aqueous solubility; hence, 
the presence of mAb inadvertently inhibited its diffusion 
through chitosan nanoparticles.
In order to elucidate the mechanisms and kinetics 
of the release of siRNA from the hybrid nanoparticles, 
mathematical models were applied.
From Tables 3 and 4, it is very clear that the release of 
antimutant-KRAS siRNA from the functionalized and 
non-functionalized hybrid nanoparticles at pH 5 fit-
ted well to both Higuchi and Korsmeyer–Peppas release 
kinetics. The correlation factors for both groups of nano-
particles were well above 0.95.
The Higuchi model describes the release of payload 
from a system as a square root of the time dependent 
processed based on Fickian diffusion [11, 29]. This model 
is defined by Eq. 1.
where, Q0 is the initial amount of payload, Qt is the 
cumulative amount of payload at time t, KH is the Higu-
chi constant.
The Korsmeyer-Peppas model describes release of pay-
load from a polymeric system. For this model, pure diffu-
sion represents the controlling release mechanism when 
n ≥ 0.5 [11, 30]. This model is defined by Eq. 2.
where KKP is the Korsmeyer-Peppas constant and n is the 
release exponent describing the release mechanism [30].
The fact that the release of siRNA from both function-
alized and non-functionalized hybrid nanoparticles fitted 
well with both Higuchi and Korsmeyer–Peppas further 
confirms that the release of siRNA from the anti-NTSR1-
mAb functionalized is not inhibited by the presence of 
the anti-NTSR1-mAb on the surface of the nanoparticles 
at this pH. Further, it also confirms that the release of 
siRNA from these nanoparticles was by Fickian diffusion. 
This is in agreement with previuos reports showing that 
the release of payloads from most nanoparticles were 
by Fickian diffusion [12]. However, the release of siRNA 
from both functionalized and non-functionalized hybrid 
nanoparticles at pH 7 did not fit any of the models stud-
ied. This could mean that the release of siRNA from these 
hybrid nanoparticles at this pH involves a combination of 
mechanisms or that the mechanism of release involved 
was not covered in this study.
Following the successful conjugation of anti-NTSR1-
mAb to the surface of the hybrid nanoparticles, it was 
essential to confirm the involvement of NTSR1 in the 
uptake of these nanoparticles by lung adenocarcinoma 
cells known to overexpress this receptor. Previous report 
(1)Qt = Q0e + KHt1/2
(2)Qt = KKPtn
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by Takahashi et  al. [31] had shown that both A549 and 
H23 lung adenocarcinoma cells overexpress this receptor. 
Reverse transcriptase PCR in Fig. 4 confirms the expres-
sion of NTSR1 in these cells. The role of this receptor in 
the uptake of siGLO-loaded anti-NTSR1-mAb function-
alized hybrid nanoparticle was confirmed using both 
fluorescence microscopy and flow cytometer. An exces-
sive amount of the neurotensin, the main ligand for this 
receptor was initially added to the culture media 60 min 
prior to the addition of the nanoparticles so as to occupy 
all available receptors [32]. Control experiments omitting 
the addition of neurotensin in the culture media for both 
cells were also carried out for comparison. Fluorescence 
microscopy (Figs. 5, 6) and flow cytometry (Fig. 7) con-
firm the specificity of the uptake of these nanoparticles 
in both A549 and H23 cells. The presence of neuroten-
sin in excess amount inhibited the interaction of the 
anti-NTSR1-mAb functionalized hybrid nanoparticles. 
This is due to the fact that most of the known effects of 
neurotensin are mediated through its specific interaction 
with NTSR1 [33, 34]. NTSR1 has been reported to bind 
neurotensin at its extracellular surface [35], hence inhib-
iting the interaction of the anti-NTSR1-mAb function-
alized hybrid nanoparticles with NTSR1 present on the 
surface of both A549 and H23 cells.
Conclusions
We reported the production of tunable novel hybrid 
nanoparticles suitable for the intracellular delivery of 
siRNAs. The particle size, loading capacity and encap-
sulation efficiency of anti-mutantKRAS siRNA in these 
nanoparticles were optimized by exploring the influence 
of the concentration of human IgG in the nanoprecipita-
tion medium and the rotation speed of the magnetic stir-
rer on critical parameters such as particle size, loading 
and encapsulation efficiency. These hybrid nanoparticles 
were successfully transformed into actively targeted nan-
oparticles by covalently binding anti-NTSR1-mAb to the 
surface. The involvement of the target receptor (NTSR1) 
in the uptake of these nanoparticles by lung adenocarci-
noma cells was confirmed using both fluorescent micros-
copy and flow cytometry. The mechanism of siRNA 
release from these actively targeted hybrid nanoparticles 
was elucidated to be by Fickian diffusion. Altogether, this 
hybrid nanoparticle delivery system can be used as a plat-
form technology for intracellular delivery of siRNAs to 
NTSR1-overexpressing tumor cells.
Materials and methods
Materials
Human IgG was purchased from Equitech Bio (Kerrville, 
TX, USA). Poloxamer-188, RNase-free water, 4,6-diami-
dino-2-phenylindole (DAPI), and fetal bovine albumin 
(FBS) were obtained from Fisher Scientific. Antineutoten-
sin receptor 1-monoclonal antiboby (anti-NTSR1-mAb 
was purchased from Santa Cruz Biotechnologies. siRNA 
against mutated KRAS G12S was designed andpurchased 
from GE Dharmacon. siG12S sense and antisense sequences 
are GUUGGAGCUAGUGGCGUAGdTdT and CUACGC 
CACUAGCUCCAACdTdT respectively. siGLO-Green 
(6-FAM-labeled) was obtained from GE Dharmacon. N-[p-
maleimidophenyl] isocyanate (PMPI), and 2-iminothiolane-
HCl were obtained form Thermo Scientific. Neurotensin 
was purchased from Abcam (Cambridge, MA, USA)
Cell line and cell culture
Adernocarcinoma cell lines A549 and H23, expressing 
KRAS mutation at G12S and G12C were obtained from 
American Type Culture Collection (ATCC), Rockville, 
MD. A549 cells were maintained in F12 K medium sup-
plemented with 10 % FBS and 1 % antibiotics. H23 cells 
cells were maintained in RPMI supplemented with 10 % 
FBS and 1 % antibiotics. Both cells were kept in a humidi-
fied air atmosphere with 5 % carbon dioxide.
Methods
siRNA‑loaded nanoparticle preparation
Hybrid nanoparticles were prepared based on our previ-
ously reported protocol [4]. 50, 75 and 100 mg milligrams 
of excipient-free human IgG was dissolved in 0.01  N 
HCl containing 20  mg of poloxamer-188 and 187 μg of 
siRNA to make a 10 mL total solution in a 50 mL beaker. 
The final concentrations of human IgG in each solution 
amounted to 5, 7.5 and 10 mg/mL. These solutions were 
then slowly titrated with 0.01 N NaOH to bring the pH 
of the mixture to 7, which is the isoelectric point (pI) of 
human IgG as determined in our laboratory using iso-
electric focusing. The nanoparticles were continuously 
mixed at different revolutions per minute (125, 250 and 
350  rpm) on a magnetic stirrer for additional 10  min. 
The length of the magnetic stirrer was kept consistent 
at 13  mm. At the pI, siRNA-loaded nanoparticles were 
spontaneously precipitated. The colloidal suspension 
was then centrifuged with a micro-centrifuge (Eppendorf 
centrifuge 5418) at 2000 rpm for 5 min. The supernatant 
was decanted, and the nanoparticles were rinsed thrice 
with double distilled deionized water. Nano particles 
were then redispersed in water before being snap-frozen 
using liquid nitrogen. This was then loaded into a freeze- 
dryer (Labconco FreezeZone 4.6), and lyophilization was 
performed for 48  h. The different parameters used for 
each nanoparticle formulation is presented in Table 5.
Thiolation of anti‑NTSR1‑mAb
Thiolation of anti-NTSR1-mAb was performed based on 
a method adopted from a previously used method [9]. 
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Briefly, 1.3 × 10−4 M of Traut’s reagent (2-Iminothiolane.
HCl) was prepared in phosphate buffered saline (pH 
7.4). 500  µl of this solution was then added to 1  mL of 
1.3 × 10−6 M (0.2 mg/mL) of anti-NTSR1-mAb solution. 
The reaction was stirred for 2  h at 25  °C. The mixture 
then centrifuged at 4000 rpm and 10 °C for 15 min using 
30 kDa cutoff centrifugal ultrafilters (Millipore Corp) to 
exclude unreacted Traut’s reagent.
Activation of hybrid nanoparticles with heterobifunctional 
cross‑linker
5  mg/mL of hybrid nanoparticles were dispersed in 
0.1 M phosphate buffer (pH 7.2). This was then added to 
2  mg/mL of N-[p-maleimidophenyl] isocyanate (PMPI), 
a heterobifunctional crosslinker that links sulfhydryl 
to hydroxyl groups [13]. PMPI was dissolved in 50  mM 
phosphate buffer (pH 8).The reaction was performed for 
3 h at 25 °C, after which the activated nanoparticles were 
centrifuged at 4000 rpm at 10 °C for 15 min using 30 kDa 
ultrafilters (Millipore Corp.)
Preparation of anti‑NTSR1‑mAb functionalized hybrid 
nanoparticles
The activated nanoparticles were finally functionalized 
with the thiolated anti-NTSR1-mAb by adding 500  µL 
of 2 mg/mL thiolated anti-NTSR1-mAb to 4 mL of acti-
vated nanoparticle suspension (5 mg/mL) and then incu-
bated for 3 h at 25  °C. The functionalized nanoparticles 
were then centrifuged for 30 min at 4000 rpm and 10 °C. 
unconjugated anti-NTSR1-mAb in the supernatant was 
quantified using Total Protein Kit (Micro Lowry, Sigma) 
based on the supplier’s instructions.
Nanoparticle characterization
Particle size distribution of the nanoparticles was meas-
ured by photon correlation spectroscopy (PCS) using 
ZetaSizer Nano ZS with DTS software (Malvern Instru-
ments, UK). Pellets formed after centrifugation and rinsing 
were redispersed in deionized water using a pipet. Inten-
sity autocorrelation was measured at a scattering angle (θ) 
of 173°. The Z-average and polydispersity index (PDI) were 
recorded in triplicate. For zeta potential measurement, 
samples were taken in a universal dip cell (Malvern Instru-
ments) and the zeta potential was recorded in triplicate.
The morphology and internal arrangements of the 
components of the nanoparticles were characterized 
by transmission electron microscopy (TEM). A drop 
of nano-particle suspension was made onto a copper 
grid coated with carbon membrane and then air-dried. 
The nanoparticles were observed using a FEI Tecnai 12 
TEM. Electron micrographs were captured with an AMT 
XR111 11 megapixel CCD camera.
Reverse Transcriptase PCR
Total RNA was isolated using Qiagen RNAeasy kit (Qiagen, 
Valencia, CA, USA), and reverse transcribed using Verzo 
cDNA kit (Thermoscientific, Waltham, MA, USA). PCR 
was carried out using 25 μl reaction mixtures containing 
1.0  μl of cDNA, 1 × Qiagen buffer, 0.2 mM of dNTP mix-
ture, 0.2 μM of each primer and 1.5 U of HotStar Taq (Qia-
gen, Valencia, CA, USA). Reactions consisted of 1 cycle at 
95  °C for 15 min followed by 35 amplification cycles (94  °C 
for 1 min, 55   °C for 1 min and 72   °C for 1 min) for neu-
rotensin receptor 1 (NR1). β-actin PCR was performed 
using the same conditions except for the annealing tem-
perature (59  °C). Primer sequences of NR1,Forward-5′-
CGTGGAGCTGTACAACTTCA-3′, reverse 5′-CAGCCA 
GCAGACCACAAAGG-3′ and β-actin, Forward 5′-CCA 
AGGCCAACCGCGAGAAGAT-3′, reverse 5′-TTGCTCG 
AAGTCCAGGGCGA-3′.
siRNA release study
Release of siRNA from non-functionalized and anti-
NTSR1-mAb functionalized hybrid nanoparticles was 
investigated using pH 5 and 7.4 acetate buffer and PBS 
respectively. Nanoparticles were suspended in 0.5 mL of 
Table 5 Variable parameters used in the formulation of different nanoparticle batches
Nanoparticle batch Concentration of human IgG 
(mg/mL)
Concentration of poloxamer‑188 
(%w/v)
Magnetic stirring rate (rpm) Amount 
of siRNA (µg)
IP-1 5 0.2 125 187
IP-2 5 0.2 250 187
IP-3 5 0.2 350 187
IP-4 7.5 0.2 125 187
IP-5 7.5 0.2 250 187
IP-6 7.5 0.2 350 187
IP-7 10 0.2 125 187
IP-8 10 0.2 250 187
IP-9 10 0.2 350 187
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a buffered solution in a tubular cellulose dialysis mem-
brane secured tightly at both ends. This was then incu-
bated in 5 mL buffered solution reservoirs at 37 °C while 
the reservoir was gently agitated. The amount of siRNA 
released at different time points was analyzed and quan-
tified for percentage cumulative release using ion-pair 
HPLC as detailed below.
Ion‑pair HPLC
siRNA quantitative analysis was performed with a Waters 
2695 separation module combined with a Waters 2998 
photodiode array detector Alliance HPLC system (Waters, 
Milford, MA, USA). A Waters XSELECT HSS C18 column 
XP (4.6 × 150 mm) was used. 1 μL of siRNA sample was 
injected using 20  mM triethylamine–acetic acid (pH 7) 
and 5–12 % acetonitrile, gradient elusion as mobile phase. 
Analysis was performed at a flow rate of 0.2 mL/min. UV 
detection was performed at 269 nm, and chromatograms 
were recorded using Empower Pro software.
Fourier transform infrared spectroscopy (FTIR)
Spectra from non-functionalized hybrid nanoparticles 
and anti-NTSR1-mAb-functionalized hybrid nanopar-
ticles were collected using a single-reflection attenuated 
total reflectance (ATR) with a diamond internal reflection 
crystal installed in a iS10 FTIR spectrometer (Thermo 
Fisher Scientific, Madison, WI, USA). Lyophilized pow-
ders were placed on the surface of the ATR crystal after 
background spectra had been collected. Spectra were col-
lected after 64 scans at 4 cm−1 resolution. Data were ana-
lyzed using OMNIC software.
Flourescence spectroscopy
To verify the presence of anti-NTSR1-mAb on the sur-
face of the hybrid nanoparticles, fluorescein isothiocyanate 
(FITC)-labeled sheep antimouse immunoglobulin (IgG) was 
incubated with the functionalized and non-functionalized 
nanoparticles at 25 °C for 2 h at a ratio of 1:1000 [14]. The 
mixtures were then centrifuged at 13,000 rpm for 15 min. 
The pellets were washed twice with PBS in order to remove 
unattached FITC-labeled sheep antimouse IgG. Fluores-
cien labeled nanoparticles were then suspended in PBS. The 
fluorescence intensity of fluorescien dye was measured at λ 
ex 494 nm and λ em 525 nm using a fluorescent microplate 
reader. This was then compared to that of non-functional-
ized hybrid nanoparticles treated with FITC-labeled sheep 
antimouse IgG, PBS and FITC-labeled antimouse IgG.
Fluorescence microscopy
A549 and H23 cells (2 ×  104 cells/well) were seeded in 
8 well coated glass slides (Discovery Labware, USA) and 
incubated for 48 h. PBS washed cells were incubated with 
anti-NTSR1-functionalized siGLO-FAM (green)-loaded 
hybrid nanoparticles suspended in the RPMI medium 
(100  μg/mL) for 6  h. Corresponding cells were initially 
treated with 1000 molar excess of neurotensin, 60  min 
before being treated with the NTSR1-functionalized 
hybrid nanoparticles. Cells were washed with siGLO-
FAM (green)-loaded hybrid nanoparticles also for 6  h. 
Cells were then washed with PBS, fixed with 2  % para-
formaldehyde, and incubated at room temperature for 
20  min. PBS washed cells were then blocked with 5  % 
BSA for 30 min at room temperature. Cells were stained 
with 4′,6-diamidino-2-phenylindole (DAPI) to visualize 
nucleus. Cells were then mounted and observed under 
a Leica DMI 6000B fluorescence microscope (Leica 
Microsystems, Exton, PA, USA).
Flow cytometry
A549 and H23 cells were used to investigate the uptake 
of functionalized siGLO-FAM loaded hybrid nanoparti-
cle. About 1 million cells/well were seeded in a 12 well 
plate and incubated for 48 h. Cells were then treated with 
100  μg/mL the FITC conjugated nanoparticles resus-
pended in RPMI medium and incubated for 6  h. Cor-
responding cells were initially treated with 1000 molar 
excess of neurotensin, 60 min before being treated with 
the NTSR1-functionalized nanoparticles. Cells were 
washed with siGLO-FAM (green)-loaded hybrid nano-
particles also for 6 h. The cells were trypsinized and cen-
trifuged at 1000 rpm for 5 min, and the pellet was washed 
and resuspended in PBS. The samples were then filtered 
through 0.75  µm cell strainer before being analyzed 
by flow cytometry (BDFACS caliber). 10000 cells were 
measured in each sample.
Statistical analysis
Results are expressed as mean ± standard deviation (SD), 
unless otherwise indicated. The difference between two 
groups was determined by two-tailed Student’s t test. A p 
value of 0.05 was taken as statistically significant.
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